Integrated Drug Development Programmes
• Project Management of many Integrated Drug Development projects from lead candidate identification through to Phase IIa Clinical Trials encompassing pre-clinical, clinical, clinical trials supplies, regulatory and pharmaceutical sciences aspects of drug development.
• Indications of projects included epilepsy, dementia, Parkinson’s disease, cardiovascular disease, rheumatoid arthritis, multiple sclerosis, metabolic disorders and oncology.
• Associate Director in Programme Management group at Quintiles responsible for line management of Project Managers, and of all departmental staff in Director’s absence.
• Acting Head of Programme Management group over transition period during acquisition by Aptuit.
• Managing multiple outsourced vendors in a range of disciplines.
Toxicology
• Project Leader in chronic and reprotoxicology studies at Syngenta (CTL).
• Researcher in mechanisms of lung, kidney and ocular toxicity in Biochemical Toxicology department at Syngenta CTL.
• Planning and conduct of toxicology studies to support Orphan Drug Designation whilst in Biochemical Toxicology department at Syngenta (CTL).
• PhD in mechanisms of haloalkene mediated nephrotoxicity.
• Senior Toxicologist involved in Study Directing and advising clients on design of general toxicology studies for regulatory submission at Inveresk Research.
Gaskin P. All in the Mind. European Pharmaceutical Contractor, in press.
Patmore L and Gaskin P. Outsourcing Strategies - from David to Goliath European Pharmaceutical Contractor, Autumn 2007, 8-12.
Lock EA, Gaskin P, Ellis M, Provan WM, Smith LL. Tyrosinemia produced by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury. Toxicology and Applied Pharmacology 2006; 215(1):9-16.
Lock EA, Gaskin P, Ellis MK, McLean Provan W, Robinson M, Smith LL. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse. Toxicology 2000; 144(1-3):179-187.
Lock EA, Ellis MK, Gaskin P, Robinson M, Auton TR, Provan WM, Smith LL, Prisbylla MP, Mutter LC, Lee DL. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. Journal of Inherited Metabolic Disorders 1998; 21(5):498-506.
Lock EA, Gaskin PJ, Ellis MK, Robinson M, Provan WM, Smith LL. The effect of a low protein diet and dietary supplementation of threonine on tyrosine and 2-(2-Nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione-induced corneal lesions, the extent of tyrosinemia, and the activity of enzymes involved in tyrosine catabolism in the rat. Toxicology and Applied Pharmacology 1998; 150:125-132.
Adcock HJ, Gaskin PJ, Shaw PN, Teesdale-Spittle PH, Buckberry LD. Novel sources of C-S lyase activity. Journal of Pharmaceutical Pharmacology 1996; 48(2): 150-153.
Lock EA, Gaskin PJ, Ellis MK, Provan WM, Robinson M, Smith LL, Prisbylla MP, Mutter LC. Tissue distribution of 2-(2-Nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat. Toxicology and Applied Pharmacology 1996; 141:439-447.
Gaskin PJ, Adcock HJ, Buckberry LD, Shaw PN. The C-S lysis of L-cysteine conjugates by aspartate and alanine aminotransferase enzymes. Human and Experimental Toxicology 1995; 14(5):422-427.
Buckberry LD, Adcock HJ, Adler J, Blagbrough IS, Gaskin PJ, Shaw PN. In vitro methods for the assessment of L-cysteine conjugate toxicity. ATLA 1994; 22:78-80.